Hemophilia: Epidemiology Forecast to 2028

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) (Bolton-Maggs and Pasi, 2003). The clinical presentation of hemophilia be at the mild, moderate, or severe stage, depending on the residual level of the circulating factor (White et al., 2001; Waure et al., 2012; Srivastava et al., 2013; Centers for Disease Control and Prevention, 2018a).

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the diagnosed prevalent cases of hemophilia A and hemophilia B in the 8MM. GlobalData epidemiologists applied country-specific prevalence rates of hemophilia A and hemophilia B, wherever available, to each country’s population to obtain the number of estimated diagnosed prevalent cases.

The following data describes epidemiology of hemophilia A and hemophilia B cases and acquired hemophilia cases. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B from 67,051 diagnosed prevalent cases in 2018 to 67,678 diagnosed prevalent cases in 2028, with an Annual Growth Rate (AGR) of 0.09% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 8MM, while Spain will have the lowest. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acquired hemophilia from 2,163 diagnosed prevalent cases in 2018 to 2,215 diagnosed prevalent cases in 2028, with an AGR of 0.24% during the forecast period. China will have the highest number of diagnosed prevalent cases of acquired hemophilia among the 8MM, while Spain will have the lowest.

Scope

The Hemophilia Epidemiology Report and Model provide an overview of the risk factors and global trends of hemophilia in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.

The hemophilia epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

 The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

 The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Hemophilia Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.

Understand magnitude of hemophilia population by severity.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status

3.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia

3.5 Epidemiological Forecast for Hemophilia A (2018–2028)

3.5.1 Diagnosed Prevalent Cases of Hemophilia A

3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A

3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A

3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity

3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors

3.6 Epidemiological Forecast for Hemophilia B (2018–2028)

3.6.1 Diagnosed Prevalent Cases of Hemophilia B

3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B

3.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B

3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity

3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors

3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018–2028)

3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

3.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia

3.8 Discussion

3.8.1 Epidemiological Forecast Insight

3.8.2 Limitations of Analysis

3.8.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Relationship of Bleeding Severity with Clotting Factor Level.

Table 2: Comorbidities for Hemophilia

Table 1: Relationship of Bleeding Severity with Clotting Factor Level.

Table 2: Comorbidities for Hemophilia

List of Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028

Figure 2: 8MM, Diagnosed Prevalent Cases ...

Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028

Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, All Ages, 2018 and 2028

Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), All Ages, 2018

Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), All Ages, 2018

Figure 5: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 6: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity

Figure 7: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

Figure 8: 8MM, Sources Used, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 9: 8MM, Sources Used, Type of Treatment Among Hemophilia A and Hemophilia B Patients

Figure 10: 8MM, Sources Used, Diagnosed Prevalent Cases of Acquired Hemophilia

Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, All Ages, Both Sexes, N, 2018

Figure 12: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, N, 2018

Figure 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, All Ages, N, 2018

Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2018

Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2018

Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, All Ages, Both Sexes, 2018

Figure 17: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, 2018

Figure 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, All Ages, N, 2018

Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2018

Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018

Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018

Figure 22: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018

Figure 23: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2018

Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2018

Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018

Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018

Figure 27: 8MM, Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018

Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, All Ages, Both Sexes, N, 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports